| For: | Liu JJ, Zhou M, Yuan T, Huang ZY, Zhang ZY. Conversion treatment for advanced intrahepatic cholangiocarcinoma: Opportunities and challenges. World J Gastroenterol 2025; 31(15): 104901 [PMID: 40309227 DOI: 10.3748/wjg.v31.i15.104901] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v31/i15/104901.htm |
| Number | Citing Articles |
| 1 |
Luca Risi, Marco Cantamessa, Lorenzo Pavia, Luca Viganò. Conversion and neoadjuvant systemic therapy for intrahepatic cholangiocarcinoma: from technical resectability to biology-driven surgical selection - a systematic review and meta-analysis. Hepatoma Research 2026; doi: 10.20517/2394-5079.2025.85
|
| 2 |
Margherita Rimini, Angela Lamarca, Masafumi Ikeda, Oluseyi Abidoye, Jessica Lucchetti, Lorenzo Antonuzzo, Jin Won Kim, Arndt Vogel, Federico Nichetti, Anna Saborowski, Tiziana Pressiani, Caterina Vivaldi, Ilario Giovanni Rapposelli, Frederik Peeters, Chiara Braconi, David J. Pinato, Emiliano Tamburini, Chiara Pircher, Stefano Tamberi, Florian Castet, Monica Verrico, Alessandro Parisi, Nuno Couto, Hong Jae Chon, Andrea Martirena, Matteo Landriscina, Fabian Finkelmeier, Ester Oneda, Antonio Avallone, Emanuela Dell'Aquila, Lukas Perkhofer, Il Hwan Kim, Vincenzo Formica, Cidalia Maria de Sousa Pinto, Ingrid Garajova, Beodeul Kang, Salvatore Corallo, Elisabetta Fenocchio, Giovanni Farinea, Alessandro Pastorino, Anna Diana, Yoo Changhoon, Marta Schirripa, Maria Grazia Rodriquenz, Mario Scartozzi, Lucrezia Zumstein, Michele Ghidini, Gerald W. Prager, Giuseppe Aprile, Gian Paolo Spinelli, Su Yung‐Yeh, Stephen L. Chan, Iakov Bolnykh, Alessia Lancianese, Tomoyuki Satake, Tanios Bekaii‐Saab, Daniele Lavacchi, Laura Passeri, Michele Ferrara, Minsu Kang, Massimo Giuseppe Viola, Silvia Bozzarelli, Mara Persano, Gianluca Masi, Rita Balsano, Monica Niger, Sara Lonardi, Francesca Salani, Silvia Camera, Francesca Ratti, Lorenzo Fornaro, Lorenza Rimassa, Andrea Casadei‐Gardini. Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real‐World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab. International Journal of Cancer 2026; doi: 10.1002/ijc.70641
|
| 3 |
Jiawei Xu, Yifan Ji, Min Feng, Zhiheng Zhang, Decai Yu. Gemcitabine-cisplatin plus durvalumab in advanced intrahepatic cholangiocarcinoma: effectiveness outcomes and characterization of the tumor microenvironment. Hepatology International 2026; 20(3) doi: 10.1007/s12072-026-11070-y
|
| 4 |
Chelsea R. Olson, Gabriela L. Aitken, Michael W. Spinrad, Evan S. Glazer. Neoadjuvant Strategies for Patients with Resectable Biliary Tract Cancers: A Review. Current Oncology 2025; 32(10) doi: 10.3390/curroncol32100584
|
| 5 |
Kizuki Yuza, Jun Kawashima, Odysseas P. Chatzipanagiotou, Christian Hobeika, Federico Aucejo, Hugo P. Marques, Tom Hugh, Feng Shen, Shishir K. Maithel, Bas Groot Koerkamp, Irinel Popescu, Minoru Kitago, Matthew J. Weiss, Guillaume Martel, Carlo Pulitano, George Poultsides, Andrea Ruzzenente, Todd W. Bauer, Ana Gleisner, Itaru Endo, Timothy M. Pawlik. Biologic stratification with tumor burden score and CA19-9 to inform vascular resection in intrahepatic cholangiocarcinoma. European Journal of Surgical Oncology 2026; 52(5) doi: 10.1016/j.ejso.2026.111750
|
| 6 |
Michele Ghidini, Fausto Petrelli, Matteo Paccagnella, Massimiliano Salati, Francesca Bergamo, Margherita Ratti, Caterina Soldà, Barbara Galassi, Ornella Garrone, Massimo Rovatti, Arianna Zefelippo, Lucio Caccamo, Enrico Gringeri, Alessandro Zerbi, Guido Torzilli, Silvia Bozzarelli, Lorenza Rimassa, Gianluca Tomasello. Prognostic Factors and Survival Outcomes in Resected Biliary Tract Cancers: A Multicenter Retrospective Analysis. Cancers 2025; 17(15) doi: 10.3390/cancers17152445
|
| 7 |
Jiawei Hu, Yihang Wang, Haoran Diao, Shuangda Miao, Xiaoxiao Zhang, Qi Li, Yanzhi Pan, Yun Jin, Yuanquan Yu, Jiangtao Li. Determinants and survival benefits of achieving textbook outcome for intrahepatic cholangiocarcinoma in the era of neoadjuvant therapy. Frontiers in Oncology 2026; 16 doi: 10.3389/fonc.2026.1737204
|
| 8 |
Zengpeng Sun, Yutao Wang, Xu Chen, Lishun Yang, Ou Li, Jia Zhou, Zhiguo Tan, Chuang Peng. Surgery vs. non-surgery for advanced cholangiocarcinoma post-conversion therapy with PD-1/PD-L1 inhibitors plus TKIs. Frontiers in Immunology 2026; 17 doi: 10.3389/fimmu.2026.1753437
|